Sign in

    Joseph Flanagan

    former analyst who was previously associated with TD Securities (USA) LLC and later joined Moore Capital Management LP as an analyst in 2025. His coverage at TD Cowen

    Joseph Flanagan is a former analyst who was previously associated with TD Securities (USA) LLC and later joined Moore Capital Management LP as an analyst in 2025. His coverage at TD Cowen or TD Securities is not explicitly detailed in public sources, and there are no published metrics on his performance track record, such as success rates or analyst rankings on major platforms. Flanagan’s prior experience also includes consulting roles, but there is no confirmation of widely recognized professional credentials or securities licenses in public regulatory databases. While his LinkedIn profile was not found to provide additional data, available records emphasize a finance-focused career with recent transition to Moore Capital Management.

    Joseph Flanagan's questions to Personalis (PSNL) leadership

    Joseph Flanagan's questions to Personalis (PSNL) leadership • Q3 2024

    Question

    Joseph Flanagan, on for Dan Brennan, asked whether the sequential strength in the pharma business was driven entirely by Moderna, or if MRD and other profiling revenues also grew, and questioned the opportunity for growth before Medicare approval.

    Answer

    CFO Aaron Tachibana confirmed that while Moderna's accelerated PCV work was the primary driver of sequential pharma growth, revenue from the ImmunoID NeXT platform and biopharma MRD projects also increased. CEO Christopher Hall added that biopharma MRD adoption is gaining traction despite long buying cycles, and he anticipates strong revenue growth from these customers in 2025, prior to clinical reimbursement.

    Ask Fintool Equity Research AI